New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
RIVM and German BfR enter cooperation agreement on animal protection and food safety The German Federal Institute of Risk Assessment (BfR) and the Dutch National Institute for Public Health and the Environment, RIVM have signed a cooperation agreement, focused on developing new sci
Integrated approach reduces harmful effects of medicines in surface waters Residues of medicinal products, such as painkillers, hormones and antidepressants, are increasingly detected in surface water and drinking water.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Breakthrough on cumulative risk assessment exposure to pesticides in food The European Commission, Member States and EFSA have taken a major step forward in their work on assessing the cumulative risks from exposure to pesticides in food.
Newborn heel prick screening starts on St Eustatius and Saba On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.
RIVM Nutrition and Food Safety expert gets top risk assessment function at EFSA As of November 1, Prof. Hans Verhagen will join the European Food Safety Authorithy (EFSA) in Parma, Italy as Head of the Risk Assessment and Scientific Assistance Department (RASA).
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.